Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Aldoss I, Zhang J, Shimamoto K, Saygin C, Robbins M, Agrawal V, Aribi A, Karaoglu DA, Pourhassan H, Koller P, Ali H, Blackmon A, Otoukesh S, Sandhu K, Ball B, Artz AS, Al Malki MM, Salhotra A, Tinajero J, Gu Z, Lagman I, Velasquez M, Dang J, Becker PS, Afkhami M, Ghoda L, Stock W, Forman SJ, Stein A, Marcucci G, Pullarkat V. Aldoss I, et al. Among authors: pullarkat v. Haematologica. 2024 Nov 7. doi: 10.3324/haematol.2024.286427. Online ahead of print. Haematologica. 2024. PMID: 39506897 Free article.
High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy.
Tinajero J, Ngo D, Zhang J, Tsai NC, Aribi A, Aldoss I, Agrawal V, Arslan S, Amanam I, Pourhassan H, Sandhu K, Al-Malki M, Pullarkat V, Becker P, Nakamura R, Stein A, Marcucci G, Artz A, Koller P, Salhotra A. Tinajero J, et al. Among authors: pullarkat v. Leuk Lymphoma. 2024 Jul;65(7):1020-1023. doi: 10.1080/10428194.2024.2332506. Epub 2024 Apr 18. Leuk Lymphoma. 2024. PMID: 38635368 No abstract available.
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
Peffault de Latour R, Röth A, Kulasekararaj AG, Han B, Scheinberg P, Maciejewski JP, Ueda Y, de Castro CM, Di Bona E, Fu R, Zhang L, Griffin M, Langemeijer SMC, Panse J, Schrezenmeier H, Barcellini W, Mauad VAQ, Schafhausen P, Tavitian S, Beggiato E, Chew LP, Gaya A, Huang WH, Jang JH, Kitawaki T, Kutlar A, Notaro R, Pullarkat V, Schubert J, Terriou L, Uchiyama M, Wong Lee Lee L, Yap ES, Sicre de Fontbrune F, Marano L, Alashkar F, Gandhi S, Trikha R, Yang C, Liu H, Kelly RJ, Höchsmann B, Kerloeguen C, Banerjee P, Levitch R, Kumar R, Wang Z, Thorburn C, Maitra S, Li S, Verles A, Dahlke M, Risitano AM. Peffault de Latour R, et al. Among authors: pullarkat v. N Engl J Med. 2024 Mar 14;390(11):994-1008. doi: 10.1056/NEJMoa2308695. N Engl J Med. 2024. PMID: 38477987
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zeidan AM, Ando K, Rauzy O, Turgut M, Wang MC, Cairoli R, Hou HA, Kwong YL, Arnan M, Meers S, Pullarkat V, Santini V, Malek K, Kiertsman F, Niolat J, Ramos PM, Menssen HD, Fenaux P, Miyazaki Y, Platzbecker U. Zeidan AM, et al. Among authors: pullarkat v. Lancet Haematol. 2024 Jan;11(1):e38-e50. doi: 10.1016/S2352-3026(23)00333-2. Epub 2023 Dec 5. Lancet Haematol. 2024. PMID: 38065203 Clinical Trial.
Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria.
Dingli D, De Castro Iii C, Koprivnikar J, Kulasekararaj A, Maciejewski J, Mulherin B, Panse J, Pullarkat V, Röth A, Shammo J, Terriou L, Weitz I, Yermilov I, Gibbs S, Broder M, Beenhouwer D, Kuter D. Dingli D, et al. Among authors: pullarkat v. Hematology. 2024 Dec;29(1):2329030. doi: 10.1080/16078454.2024.2329030. Epub 2024 Mar 21. Hematology. 2024. PMID: 39665683 Free article.
Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease.
Blackmon A, Afkhami M, Yang D, Mokhtari S, Samara Y, Pourhassan H, Ball B, Salhotra A, Agrawal V, Sandhu K, Desai A, Otoukesh S, Arslan S, Amanam I, Koller P, Tinajero J, Aribi A, Aldoss I, Becker P, Artz A, Ali H, Stein A, Smith E, Pullarkat V, Forman SJ, Marcucci G, Nakamura R, Al Malki MM. Blackmon A, et al. Among authors: pullarkat v. Bone Marrow Transplant. 2024 Dec 18. doi: 10.1038/s41409-024-02491-0. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39695333
Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes.
Tinajero J, Xu S, Ngo D, Li S, Palmer J, Nguyen T, Stein A, Koller P, Agrawal V, Pourhassan H, Murphy L, Forman S, Douer D, Marcucci G, Pullarkat V, Aldoss I. Tinajero J, et al. Among authors: pullarkat v. Br J Haematol. 2024 Nov 6. doi: 10.1111/bjh.19880. Online ahead of print. Br J Haematol. 2024. PMID: 39505575
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L; ROCCA Consortium. Roloff GW, et al. Among authors: pullarkat v. J Clin Oncol. 2024 Oct 17:JCO2400321. doi: 10.1200/JCO.24.00321. Online ahead of print. J Clin Oncol. 2024. PMID: 39418622
219 results